TD Cowen Reiterates Buy Rating on Abbvie (ABBV)

TD Cowen analyst Steve Scala reiterated a Buy rating and $180.00 price target on Abbvie (NYSE: ABBV).

The analyst commented, "Post strong Q1 results, we raised sales and EPS estimate in 2024-25 and made no EPS forecast changes thereafter when EPS are expected to accelerate. We don't view Humira as a downside risk, note much news for ABBV is upcoming, and believe ABBV's current valuation offers an attractive entry point."

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $161.28 yesterday.

You May Also Be Interested In

• Abbvie (ABBV) PT Raised to $300 at Wells Fargo
• Guggenheim Starts CalciMedica (CALC) at Buy
• Macquarie Downgrades Kuaishou Technology (1024:HK) to Underperform